“Shift[ing] the impetus” from Genetic testing to Scoring Systems, and even discouraging Genetic testing.

Dr. Seth Baum was highly paid by Aegerion. Now he is highly paid by Amgen. He proposed an algorithm for identifying FH patients. He is also treasurer for the FH Foundation, a charity funded by big pharma, and this foundation also promotes an algorithm. The word “Algorithm” sounds sophisticated and full of the future. But a common recipe for chocolate chip cookies is an algorithm.  Setting this FH scheme to the tune of an “algorithm,” applied to a computer database of patients, only leverages the consequences of the error. Reading the pharma-funded reports, it is at the highest priority to keep the scoring systems front and center and genetic testing at a lower priority … just barely in there to locate those who would otherwise be left behind.  Although identifying the lower scoring, milder FH is of high value, correctly diagnosing the severe non-FH within those FH phenotypic results should not be neglected. This extensive pattern of emphasizing the non-genetic approach to this admittedly genetic disease suggests orchestration and coordination.

“Shift[ing] the impetus” from Genetic testing to Scoring Systems, and even discouraging Genetic testing.